Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53.
Aspirin (acetylsalicylic acid, ASA) is effective in the primary and secondary prevention of vascular events. This effect is mediated in large part by platelet inhibition; however, non-platelet-mediated effects may also be relevant in the overall efficacy of ASA. We determined the effect of ASA on the synthesis of DNA and total proteins in cultured human coronary endothelial cells (HCAECs). Fourth generation HCAECs were cultured and treated with ASA and rate of synthesis of DNA and total proteins was determined by incorporation of [3H]thymidine and [3H]proline, respectively. ASA inhibited DNA synthesis by 50% at a concentration of 1mM and protein synthesis by 50% at a concentration of 2mM. The inhibitory effect of ASA was observed as early as 2h after treatment of HCAECs. The inhibition of DNA and protein synthesis could be reversed within 24h after removal of the drug from the culture medium. Indomethacin also inhibited DNA and protein synthesis. Western blot analysis revealed that the expression of p53 protein was increased after treatment of the cells with ASA. These observations indicate that ASA decreases endothelial cell proliferation through cell cycle arrest mediated by enhanced p53 expression. Arrest of endothelial proliferation and activation may be an important mechanism of the beneficial effect of ASA in acute coronary syndromes.
Ranganathan
Subramanian
S
Department of Medicine, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St., Mail Slot 532, Little Rock, AR 72205-7199, USA.
Joseph
Jacob
J
Mehta
Jawahar L
JL
D001158:Arteries / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D003326:Coronary Circulation / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation / Q000502:physiology*
D016861:Cyclooxygenase Inhibitors; D016159:Tumor Suppressor Protein p53; D004247:DNA; D001241:Aspirin; D007213:Indomethacin